Please note that the fax will no longer be available after the relocation. The new contact information is as follows: (The phone number remains unchanged.)
| New Address： | Room 907-908, BEIJING FORTUNE BUILDING, No.5, Dongsanhuan North Road, Chaoyang District, Beijing 100027 CHINA |
|---|---|
| Phone： | +86-10-8526-1158 |
| Fax： | ー |
GuNA™ is one of the artificial bridged types of modified nucleic acids using Luxna’s modified nucleic acid technologies (Luxna XNAs technology) and is used as a raw material for nucleic acid therapeutics. Compared to conventional modified nucleic acids, it is expected to improve affinity with target RNA and reduce neurotoxicity.
Inabata will pay Luxna an undisclosed upfront payment upon the execution of the License Agreement.
Additionally, Inabata will pay Luxna milestone payments and royalties based on the future production and sales of GuNA™ by Inabata.
Inabata will not develop nucleic acid therapeutics using the licensed product and will focus on the manufacturing and supplying of amidites as raw materials.
Inabata has identified the life sciences and healthcare field as one of the key areas in our mid-term management plan. By expanding sales of GuNA™, Inabata will contribute to the future growth of the nucleic acid therapeutics market and the advancement of research and development.
About Luxna XNAs Technology
Luxna XNAs Technology collectively means an innovative nucleic acid group of AmNA™, scpBNA™, GuNA™, and 5’-CP™ originated in Professor Obika’s laboratory at the Osaka University Graduate School of Pharmaceutical Sciences, Bioorganic Chemistry. Luxna XNAs Technology could make available ASOs with high activity and low toxicity by taking advantage of its characteristics of strong binding to mRNA and/or reduced immune response.
About GuNA™
GuNA™ has a positive charge, and its introduction into antisense nucleic acids can improve its binding affinity to RNA and nuclease resistance, reducing neurotoxicity, reducing immunogenicity, and prolonging the duration of action. We also expect similar effects among antisense nucleic acids, not only for knockdown but also for splicing control applications.
About nucleic acid therapeutics
Nucleic acid therapeutics are chemically synthesized drugs that use nucleotides - the building blocks of DNA and RNA - as their fundamental backbone. Unlike conventional drugs that primarily act on proteins or the pathways that produce them, nucleic acid therapeutics directly target upstream genetic information such as mRNA and non-coding RNA. This enables highly sequence-specific modulation of gene expression and allows access to intracellular targets that have been difficult to reach with traditional pharmaceuticals. Because these molecules are produced through chemical synthesis, candidate compounds can be generated rapidly, supporting their development as a next-generation class of medicines.
About Amidite
Amidite refers to a phosphoramidite-activated nucleoside, which serves as the monomer used in solid-phase synthesis of oligonucleotides. These oligonucleotides function as the active pharmaceutical ingredients in nucleic acid therapeutics.
About LuxnaBiotech
Luxna is a biotech founded in 2017 to develop safer and more effective oligonucleotide therapies (OTs) for practical use with the drug discovery platform, called LuxiAP™, based on modified nucleic acids originated in Professor Obika’s laboratory at Osaka University Graduate School of Pharmaceutical Sciences. Its purpose is to bring OTs to patients with difficult-to-treat diseases. With antisense nucleic acids as our primary development focus, Luxna actively pursues both collaborative development with several pharmaceutical companies and development on our own.
For more information: Luxnabiotech.co.jp
Follow us on social media: LinkedIn
About Inabata & Co., Ltd.
Founded in 1890, Inabata & Co., Ltd. is a global chemical trading company with approximately 70 locations in 19 countries. The company operates across four core business segments: Information & Electronics, Chemicals, Life Industry, and Plastics.
Within the Life Sciences Division of the Life Industry segment, Inabata provides end to end solutions tailored to customer needs. In addition to having active pharmaceutical ingredient (API) and intermediate manufacturing facilities in France, Inabata provides comprehensive solutions tailored to our customers' needs. These include sourcing pharmaceutical raw materials domestically and internationally, CDMO management, and logistics support for overseas distribution. Recently, Inabata has strengthened our handling of products related to new modalities such as regenerative medicine and nucleic acid therapeutics. By contributing to the revitalization of the pharmaceutical market and the promotion of research and development, Inabata aims to help realize healthy and comfortable lives.
For more information: /
For inquiries, please contact:
Inabata & Co., Ltd.
luxnabiotech@inabata.com
Company HP : /english/
Luxna Biotech Co., Ltd.
info@luxnabiotech.co.jp
Company HP : https://luxnabiotech.co.jp/en/ ]]>
(phone and fax numbers remain unchanged)
| New Address： | Room 2301, 23/F, Centralcon Tower, NO.3088 Jintian Road, Futian District, Shenzhen 518016 CHINA |
|---|---|
| Phone： | +86-755-82690772 |
| Fax： | +86-755-82690771 |
The award ceremony was originally planned to be held at Malacanang Palace, the official residence of the president of the Philippines, with the award presented by President Marcos. However, the ceremony was suddenly postponed due to the approach of a large typhoon. The award was later presented by Maria Cristina Roque, secretary of the Department of Trade and Industry; Tereso Panga, director general of PEZA; and Vivian Santos, deputy director general of PEZA, instead.
From left: PEZA Deputy Director General Vivian Santo, Department of Trade and Industry Secretary Maria Cristina Roque, Inabata Philippines President Masahiro Ogura, PEZA Director General Tereso Panga.
This award was given to Inabata Philippines in recognition of a variety of initiatives, including compliance with PEZA’s policies, efficient warehouse management, sustainable technical investments, comprehensive benefits packages for employees, and proactive CSR activities.
*PEZA: Public organization that handles the development, management, and supervision of economic zones established by the government and that draws in domestic and foreign investments to stimulate the export industry and create jobs.
From left: Marifie Caniete and Donna Samonte of Inabata Philippines, Inabata Philippines President Masahiro Ogura, PEZA Deputy Director General Vivian Santos, Janet Contreras, Ronalyn Lobos, and Joi Yambao of Inabata Philippines.
For Inquires, contact:
Corporate Communications Department, General Affairs Office
Inabata & Co., Ltd.
Email: corporate_comms@inabata.com
Founder Inabata Manga – Unravelling the legacy "The Tales of Katsutaro Inabata"
Over 130 years ago, during the Meiji era, Founder Katsutaro Inabata started the company. With the desire to share the story of how he came to establish it as clearly as possible, we decided to create a manga.
The story begins with seven-year-old Katsutaro helping his family's wagashi shop before entering school. It follows his journey, including studying in France at the age of 15, working for the Kyoto Prefectural Government upon his return, and ultimately founding his company at the age of 28. The series will be serialized in ten chapters.
The storyline is based on historical accounts published in biographical books, with some functional elements added for a creative twist.
The manga was produced under the direction of LEGIKA (in Japanese only), a non-profit organization managing the Tokiwa-so Project, with writer Yuko Shimada and manga artist Kazuya Ogata. We sincerely hope this manga offers a glimpse into the origins of our company and the life and vision of our founder.
Please enjoy the series at the link below:
/english/ik/manga/
